On Monday, President Trump is anticipated to make an announcement regarding autism, which is likely to involve advising pregnant women to avoid using Tylenol. This comes alongside the introduction of a therapy for the neurodevelopmental disorder, according to a source.

U.S. Health Secretary Robert F. Kennedy Jr. will join Trump in the Oval Office for the announcement, the details of which have been the subject of speculation since Kennedy earlier this year promised to unravel the mystery of increasing autism diagnoses within the U.S.

A source tells that specifically, the Trump administration will advise pregnant women to avoid using Tylenol, except for high fevers. Researchers have suggested there may be a link between autism and acetaminophen, Tylenol’s active ingredient, because it can cross the placenta to the fetus.

Other medical experts say such a link is not established science, and Tylenol maker Kenvue has said flatly, “there is no causal link between acetaminophen use during pregnancy and autism.”

Meantime, also has learned the Trump administration will highlight leucovorin, also known as folinic acid, as a potential therapy for people who have autism.

The Trump administration’s attempt to identify measures preventing autism has worried some physicians and health advocates, who fear Kennedy will go after established vaccines. Kennedy is considered a vaccine skeptic and is seen as trying to revamp the Centers for Disease Control and Prevention to reflect his views.